- Home
- NRO vs NTHI Comparison
NRO vs NTHI Comparison
Compare NRO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- NTHI
- Stock Information
- Founded
- NRO 2003
- NTHI 2008
- Country
- NRO United States
- NTHI United States
- Employees
- NRO N/A
- NTHI N/A
- Industry
- NRO Finance/Investors Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- NTHI Health Care
- Exchange
- NRO Nasdaq
- NTHI Nasdaq
- Market Cap
- NRO 199.6M
- NTHI 211.9M
- IPO Year
- NRO N/A
- NTHI N/A
- Fundamental
- Price
- NRO $3.19
- NTHI $11.01
- Analyst Decision
- NRO
- NTHI
- Analyst Count
- NRO 0
- NTHI 0
- Target Price
- NRO N/A
- NTHI N/A
- AVG Volume (30 Days)
- NRO 239.4K
- NTHI 40.2K
- Earning Date
- NRO 01-01-0001
- NTHI 12-18-2025
- Dividend Yield
- NRO 11.41%
- NTHI N/A
- EPS Growth
- NRO N/A
- NTHI N/A
- EPS
- NRO N/A
- NTHI N/A
- Revenue
- NRO N/A
- NTHI $59,990.00
- Revenue This Year
- NRO N/A
- NTHI N/A
- Revenue Next Year
- NRO N/A
- NTHI N/A
- P/E Ratio
- NRO N/A
- NTHI N/A
- Revenue Growth
- NRO N/A
- NTHI N/A
- 52 Week Low
- NRO $2.51
- NTHI $3.20
- 52 Week High
- NRO $3.45
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- NRO 49.70
- NTHI N/A
- Support Level
- NRO $3.13
- NTHI N/A
- Resistance Level
- NRO $3.21
- NTHI N/A
- Average True Range (ATR)
- NRO 0.03
- NTHI 0.00
- MACD
- NRO 0.00
- NTHI 0.00
- Stochastic Oscillator
- NRO 64.44
- NTHI 0.00
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).